



## Plant Virus Infection Immunity and Control

Guest Editor:

**Dr. Kathleen Hefferon**

Department of Cell and Systems  
Biology, Cornell University,  
Ithaca, NY 14850, USA

Deadline for manuscript  
submissions:

**closed (18 October 2022)**

### Message from the Guest Editor

Dear Colleagues,

A significant challenge in cancer treatment is improving health outcomes by specifically targeting biologics to tumor cells. Plant virus-based nanotechnology holds great promise for this as well as other applications, such as cancer vaccine production. Plant viruses are biodegradable and easy to produce and have no cold chain requirements. Plant viruses also naturally occur in a diversity of shapes and sizes and are nontoxic to mammalian cells. Several different plant virus capsid proteins (CP) are known to elicit immune responses. For this reason, plant viruses have found a niche in the future of medical research and development. This Special Issue thus serves to focus on the great utility of plant viruses for therapeutic applications.

Dr. Kathleen Hefferon  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)